CM559 / Keymed Biosciences - LARVOL DELTA

Study of CM559 in Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Keymed Biosciences Co.Ltd | Not yet recruiting ➔ Recruiting

Enrollment open

Study of CM559 in Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Keymed Biosciences Co.Ltd

New P1 trial

11 Class 1 innovative drugs were approved for clinical trials in China for the first time!… [Google translation] (Sina Corp) - "Mengke Pharmaceuticals' Class 1 new drug MRX-5 tablets have been approved for clinical trials. The product is intended to treat infections caused by nontuberculous mycobacteria (NTM) that are sensitive to this product...Beite Pharmaceuticals' Class 1 new drug BPR-30221616 injection has been approved for clinical trials and is intended to be developed to treat transthyretin amyloid cardiomyopathy...The Class 1 new drug CM559 injection applied by Conoya has been approved for clinical trials and is intended to be developed to treat Alzheimer's disease...The Class 1 new drug ART101 injection filed by Ontop Biopharmaceuticals has been approved for clinical trials and is intended to be developed for the treatment of hypertension....Sanofi 's Class 1 new drug SAR442970 injection has been approved for clinical use and is intended to treat primary focal segmental glomerulosclerosis (FSGS) or primary minimal change nephropathy (MCD) in adults and adolescents aged 16 and above."

New trial • Alzheimer's Disease • Cardiomyopathy • Focal Segmental Glomerulosclerosis • Hypertension • Nontuberculous Mycobacterial Disease